nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—RET—autonomic nervous system—rectum cancer	0.0183	0.0347	CbGeAlD
Vandetanib—PTK6—renal system—rectum cancer	0.00691	0.0131	CbGeAlD
Vandetanib—PTK6—urethra—rectum cancer	0.00679	0.0129	CbGeAlD
Vandetanib—PTK6—mammalian vulva—rectum cancer	0.00647	0.0123	CbGeAlD
Vandetanib—LTK—female reproductive system—rectum cancer	0.00578	0.011	CbGeAlD
Vandetanib—BMPR1B—epithelium—rectum cancer	0.00565	0.0107	CbGeAlD
Vandetanib—PTK6—female reproductive system—rectum cancer	0.00554	0.0105	CbGeAlD
Vandetanib—RIPK2—seminal vesicle—rectum cancer	0.0051	0.00967	CbGeAlD
Vandetanib—PTK6—vagina—rectum cancer	0.00501	0.0095	CbGeAlD
Vandetanib—IRAK4—seminal vesicle—rectum cancer	0.00498	0.00945	CbGeAlD
Vandetanib—EPHA6—female reproductive system—rectum cancer	0.00462	0.00876	CbGeAlD
Vandetanib—PLK4—female reproductive system—rectum cancer	0.00456	0.00865	CbGeAlD
Vandetanib—FGR—seminal vesicle—rectum cancer	0.00453	0.00859	CbGeAlD
Vandetanib—FLT4—epithelium—rectum cancer	0.00445	0.00845	CbGeAlD
Vandetanib—RIPK2—epithelium—rectum cancer	0.00443	0.00841	CbGeAlD
Vandetanib—SLK—seminal vesicle—rectum cancer	0.00434	0.00823	CbGeAlD
Vandetanib—TYRO3—female reproductive system—rectum cancer	0.00428	0.00813	CbGeAlD
Vandetanib—VEGFA—smooth muscle tissue—rectum cancer	0.00426	0.00808	CbGeAlD
Vandetanib—ERBB3—epithelium—rectum cancer	0.00424	0.00805	CbGeAlD
Vandetanib—FYN—seminal vesicle—rectum cancer	0.00422	0.00801	CbGeAlD
Vandetanib—BMPR1B—female reproductive system—rectum cancer	0.0042	0.00796	CbGeAlD
Vandetanib—MAP3K19—female reproductive system—rectum cancer	0.0042	0.00796	CbGeAlD
Vandetanib—MAP4K5—seminal vesicle—rectum cancer	0.00412	0.00782	CbGeAlD
Vandetanib—FMO1—renal system—rectum cancer	0.00408	0.00773	CbGeAlD
Vandetanib—RIPK2—urethra—rectum cancer	0.00404	0.00766	CbGeAlD
Vandetanib—VEGFA—urethra—rectum cancer	0.00402	0.00764	CbGeAlD
Vandetanib—FMO1—urethra—rectum cancer	0.004	0.0076	CbGeAlD
Vandetanib—EGFR—mammalian vulva—rectum cancer	0.00396	0.00752	CbGeAlD
Vandetanib—IRAK4—urethra—rectum cancer	0.00394	0.00748	CbGeAlD
Vandetanib—EPHB6—seminal vesicle—rectum cancer	0.00394	0.00748	CbGeAlD
Vandetanib—ERBB3—renal system—rectum cancer	0.00393	0.00746	CbGeAlD
Vandetanib—RET—epithelium—rectum cancer	0.00393	0.00746	CbGeAlD
Vandetanib—EPHA5—vagina—rectum cancer	0.00387	0.00735	CbGeAlD
Vandetanib—VEGFA—mammalian vulva—rectum cancer	0.00383	0.00727	CbGeAlD
Vandetanib—FMO1—mammalian vulva—rectum cancer	0.00381	0.00723	CbGeAlD
Vandetanib—YES1—seminal vesicle—rectum cancer	0.00381	0.00723	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—rectum cancer	0.00377	0.00716	CbGeAlD
Vandetanib—IRAK4—mammalian vulva—rectum cancer	0.00375	0.00712	CbGeAlD
Vandetanib—RET—renal system—rectum cancer	0.00365	0.00692	CbGeAlD
Vandetanib—FLT3—female reproductive system—rectum cancer	0.00364	0.00691	CbGeAlD
Vandetanib—MKNK1—urethra—rectum cancer	0.00363	0.00688	CbGeAlD
Vandetanib—FGR—urethra—rectum cancer	0.00358	0.0068	CbGeAlD
Vandetanib—LCK—urethra—rectum cancer	0.00358	0.0068	CbGeAlD
Vandetanib—TEK—epithelium—rectum cancer	0.00358	0.0068	CbGeAlD
Vandetanib—STK35—female reproductive system—rectum cancer	0.00357	0.00677	CbGeAlD
Vandetanib—AXL—urethra—rectum cancer	0.00357	0.00677	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—rectum cancer	0.00353	0.0067	CbGeAlD
Vandetanib—MKNK1—mammalian vulva—rectum cancer	0.00345	0.00655	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—rectum cancer	0.00345	0.00655	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—rectum cancer	0.00345	0.00655	CbGeAlD
Vandetanib—SLK—urethra—rectum cancer	0.00343	0.00652	CbGeAlD
Vandetanib—BLK—lymph node—rectum cancer	0.00342	0.00648	CbGeAlD
Vandetanib—FGR—mammalian vulva—rectum cancer	0.00341	0.00647	CbGeAlD
Vandetanib—LCK—mammalian vulva—rectum cancer	0.00341	0.00647	CbGeAlD
Vandetanib—FYN—renal system—rectum cancer	0.0034	0.00645	CbGeAlD
Vandetanib—AXL—mammalian vulva—rectum cancer	0.0034	0.00645	CbGeAlD
Vandetanib—LTK—lymph node—rectum cancer	0.00338	0.00641	CbGeAlD
Vandetanib—MAP2K5—seminal vesicle—rectum cancer	0.00337	0.00639	CbGeAlD
Vandetanib—KDR—seminal vesicle—rectum cancer	0.00337	0.00639	CbGeAlD
Vandetanib—FYN—urethra—rectum cancer	0.00334	0.00634	CbGeAlD
Vandetanib—TEK—renal system—rectum cancer	0.00332	0.0063	CbGeAlD
Vandetanib—FLT4—female reproductive system—rectum cancer	0.00331	0.00628	CbGeAlD
Vandetanib—FMO3—mammalian vulva—rectum cancer	0.00329	0.00625	CbGeAlD
Vandetanib—RIPK2—female reproductive system—rectum cancer	0.00329	0.00624	CbGeAlD
Vandetanib—SLK—mammalian vulva—rectum cancer	0.00327	0.00621	CbGeAlD
Vandetanib—TEK—urethra—rectum cancer	0.00326	0.00619	CbGeAlD
Vandetanib—MAP4K5—urethra—rectum cancer	0.00326	0.00619	CbGeAlD
Vandetanib—STK35—vagina—rectum cancer	0.00323	0.00612	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—rectum cancer	0.00319	0.00605	CbGeAlD
Vandetanib—SRC—epithelium—rectum cancer	0.00318	0.00604	CbGeAlD
Vandetanib—FYN—mammalian vulva—rectum cancer	0.00318	0.00603	CbGeAlD
Vandetanib—ERBB3—female reproductive system—rectum cancer	0.00315	0.00598	CbGeAlD
Vandetanib—ABL2—vagina—rectum cancer	0.00315	0.00597	CbGeAlD
Vandetanib—EPHB6—urethra—rectum cancer	0.00312	0.00592	CbGeAlD
Vandetanib—MAP4K5—mammalian vulva—rectum cancer	0.00311	0.0059	CbGeAlD
Vandetanib—YES1—renal system—rectum cancer	0.00307	0.00582	CbGeAlD
Vandetanib—SRC—smooth muscle tissue—rectum cancer	0.00307	0.00582	CbGeAlD
Vandetanib—STK10—renal system—rectum cancer	0.00304	0.00577	CbGeAlD
Vandetanib—YES1—urethra—rectum cancer	0.00301	0.00572	CbGeAlD
Vandetanib—RIPK2—vagina—rectum cancer	0.00298	0.00565	CbGeAlD
Vandetanib—EPHB6—mammalian vulva—rectum cancer	0.00297	0.00563	CbGeAlD
Vandetanib—VEGFA—vagina—rectum cancer	0.00297	0.00563	CbGeAlD
Vandetanib—MKNK1—female reproductive system—rectum cancer	0.00296	0.00561	CbGeAlD
Vandetanib—FMO1—vagina—rectum cancer	0.00295	0.0056	CbGeAlD
Vandetanib—SRC—renal system—rectum cancer	0.00295	0.0056	CbGeAlD
Vandetanib—KDR—epithelium—rectum cancer	0.00293	0.00555	CbGeAlD
Vandetanib—FGR—female reproductive system—rectum cancer	0.00292	0.00554	CbGeAlD
Vandetanib—PDGFRB—seminal vesicle—rectum cancer	0.00292	0.00553	CbGeAlD
Vandetanib—AXL—female reproductive system—rectum cancer	0.00291	0.00552	CbGeAlD
Vandetanib—IRAK4—vagina—rectum cancer	0.00291	0.00551	CbGeAlD
Vandetanib—YES1—mammalian vulva—rectum cancer	0.00287	0.00544	CbGeAlD
Vandetanib—STK10—mammalian vulva—rectum cancer	0.00284	0.0054	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—rectum cancer	0.00282	0.00535	CbGeAlD
Vandetanib—FYN—female reproductive system—rectum cancer	0.00272	0.00517	CbGeAlD
Vandetanib—KDR—renal system—rectum cancer	0.00272	0.00515	CbGeAlD
Vandetanib—MKNK1—vagina—rectum cancer	0.00267	0.00507	CbGeAlD
Vandetanib—PLK4—lymph node—rectum cancer	0.00267	0.00506	CbGeAlD
Vandetanib—KDR—urethra—rectum cancer	0.00267	0.00506	CbGeAlD
Vandetanib—MAP2K5—urethra—rectum cancer	0.00267	0.00506	CbGeAlD
Vandetanib—MAP4K5—female reproductive system—rectum cancer	0.00266	0.00505	CbGeAlD
Vandetanib—TEK—female reproductive system—rectum cancer	0.00266	0.00505	CbGeAlD
Vandetanib—FGR—vagina—rectum cancer	0.00264	0.00501	CbGeAlD
Vandetanib—LCK—vagina—rectum cancer	0.00264	0.00501	CbGeAlD
Vandetanib—AXL—vagina—rectum cancer	0.00263	0.00499	CbGeAlD
Vandetanib—ABL1—seminal vesicle—rectum cancer	0.0026	0.00493	CbGeAlD
Vandetanib—FMO3—vagina—rectum cancer	0.00255	0.00484	CbGeAlD
Vandetanib—KDR—mammalian vulva—rectum cancer	0.00254	0.00482	CbGeAlD
Vandetanib—MAP2K5—mammalian vulva—rectum cancer	0.00254	0.00482	CbGeAlD
Vandetanib—PDGFRB—epithelium—rectum cancer	0.00253	0.00481	CbGeAlD
Vandetanib—SLK—vagina—rectum cancer	0.00253	0.00481	CbGeAlD
Vandetanib—FYN—vagina—rectum cancer	0.00246	0.00467	CbGeAlD
Vandetanib—YES1—female reproductive system—rectum cancer	0.00246	0.00466	CbGeAlD
Vandetanib—BMPR1B—lymph node—rectum cancer	0.00246	0.00466	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—rectum cancer	0.00244	0.00463	CbGeAlD
Vandetanib—STK10—female reproductive system—rectum cancer	0.00243	0.00462	CbGeAlD
Vandetanib—MAP4K5—vagina—rectum cancer	0.00241	0.00457	CbGeAlD
Vandetanib—SRC—female reproductive system—rectum cancer	0.00236	0.00449	CbGeAlD
Vandetanib—PDGFRB—renal system—rectum cancer	0.00235	0.00446	CbGeAlD
Vandetanib—PDGFRB—urethra—rectum cancer	0.00231	0.00438	CbGeAlD
Vandetanib—EPHB6—vagina—rectum cancer	0.0023	0.00436	CbGeAlD
Vandetanib—YES1—vagina—rectum cancer	0.00222	0.00422	CbGeAlD
Vandetanib—STK10—vagina—rectum cancer	0.0022	0.00418	CbGeAlD
Vandetanib—PDGFRB—mammalian vulva—rectum cancer	0.0022	0.00417	CbGeAlD
Vandetanib—ABL1—smooth muscle tissue—rectum cancer	0.00218	0.00413	CbGeAlD
Vandetanib—KDR—female reproductive system—rectum cancer	0.00217	0.00413	CbGeAlD
Vandetanib—MAP2K5—female reproductive system—rectum cancer	0.00217	0.00413	CbGeAlD
Vandetanib—FLT3—lymph node—rectum cancer	0.00213	0.00404	CbGeAlD
Vandetanib—ABL1—renal system—rectum cancer	0.00209	0.00397	CbGeAlD
Vandetanib—STK35—lymph node—rectum cancer	0.00209	0.00396	CbGeAlD
Vandetanib—ABL1—urethra—rectum cancer	0.00206	0.0039	CbGeAlD
Vandetanib—ABL2—lymph node—rectum cancer	0.00203	0.00386	CbGeAlD
Vandetanib—EGFR—lymph node—rectum cancer	0.00199	0.00377	CbGeAlD
Vandetanib—ABCC1—seminal vesicle—rectum cancer	0.00198	0.00376	CbGeAlD
Vandetanib—KDR—vagina—rectum cancer	0.00197	0.00373	CbGeAlD
Vandetanib—MAP2K5—vagina—rectum cancer	0.00197	0.00373	CbGeAlD
Vandetanib—ABL1—mammalian vulva—rectum cancer	0.00196	0.00372	CbGeAlD
Vandetanib—FLT4—lymph node—rectum cancer	0.00194	0.00367	CbGeAlD
Vandetanib—RIPK2—lymph node—rectum cancer	0.00192	0.00365	CbGeAlD
Vandetanib—VEGFA—lymph node—rectum cancer	0.00192	0.00364	CbGeAlD
Vandetanib—FMO1—lymph node—rectum cancer	0.00191	0.00362	CbGeAlD
Vandetanib—PDGFRB—female reproductive system—rectum cancer	0.00188	0.00357	CbGeAlD
Vandetanib—IRAK4—lymph node—rectum cancer	0.00188	0.00357	CbGeAlD
Vandetanib—ERBB3—lymph node—rectum cancer	0.00184	0.0035	CbGeAlD
Vandetanib—ORM1—female reproductive system—rectum cancer	0.00177	0.00335	CbGeAlD
Vandetanib—MKNK1—lymph node—rectum cancer	0.00173	0.00328	CbGeAlD
Vandetanib—LCK—lymph node—rectum cancer	0.00171	0.00324	CbGeAlD
Vandetanib—FGR—lymph node—rectum cancer	0.00171	0.00324	CbGeAlD
Vandetanib—RET—lymph node—rectum cancer	0.00171	0.00324	CbGeAlD
Vandetanib—PDGFRB—vagina—rectum cancer	0.0017	0.00323	CbGeAlD
Vandetanib—AXL—lymph node—rectum cancer	0.0017	0.00323	CbGeAlD
Vandetanib—ABL1—female reproductive system—rectum cancer	0.00168	0.00318	CbGeAlD
Vandetanib—FMO3—lymph node—rectum cancer	0.00165	0.00313	CbGeAlD
Vandetanib—ABCG2—seminal vesicle—rectum cancer	0.00164	0.00311	CbGeAlD
Vandetanib—SLK—lymph node—rectum cancer	0.00164	0.00311	CbGeAlD
Vandetanib—FYN—lymph node—rectum cancer	0.00159	0.00302	CbGeAlD
Vandetanib—ABCC1—urethra—rectum cancer	0.00157	0.00297	CbGeAlD
Vandetanib—MAP4K5—lymph node—rectum cancer	0.00156	0.00295	CbGeAlD
Vandetanib—TEK—lymph node—rectum cancer	0.00156	0.00295	CbGeAlD
Vandetanib—ABL1—vagina—rectum cancer	0.00152	0.00288	CbGeAlD
Vandetanib—ABCC1—mammalian vulva—rectum cancer	0.00149	0.00283	CbGeAlD
Vandetanib—EPHB6—lymph node—rectum cancer	0.00149	0.00282	CbGeAlD
Vandetanib—YES1—lymph node—rectum cancer	0.00144	0.00273	CbGeAlD
Vandetanib—STK10—lymph node—rectum cancer	0.00142	0.0027	CbGeAlD
Vandetanib—SRC—lymph node—rectum cancer	0.00138	0.00262	CbGeAlD
Vandetanib—ABCG2—urethra—rectum cancer	0.0013	0.00246	CbGeAlD
Vandetanib—MAP2K5—lymph node—rectum cancer	0.00127	0.00241	CbGeAlD
Vandetanib—KDR—lymph node—rectum cancer	0.00127	0.00241	CbGeAlD
Vandetanib—ABCG2—mammalian vulva—rectum cancer	0.00124	0.00234	CbGeAlD
Vandetanib—ABCC1—vagina—rectum cancer	0.00116	0.00219	CbGeAlD
Vandetanib—PDGFRB—lymph node—rectum cancer	0.0011	0.00209	CbGeAlD
Vandetanib—ORM1—lymph node—rectum cancer	0.00103	0.00196	CbGeAlD
Vandetanib—ABL1—lymph node—rectum cancer	0.000981	0.00186	CbGeAlD
Vandetanib—ABCG2—vagina—rectum cancer	0.000957	0.00182	CbGeAlD
Vandetanib—CYP3A4—renal system—rectum cancer	0.00092	0.00175	CbGeAlD
Vandetanib—ALB—lymph node—rectum cancer	0.000906	0.00172	CbGeAlD
Vandetanib—ABCC1—lymph node—rectum cancer	0.000747	0.00142	CbGeAlD
Vandetanib—CYP3A4—female reproductive system—rectum cancer	0.000737	0.0014	CbGeAlD
Vandetanib—ABCG2—lymph node—rectum cancer	0.000619	0.00117	CbGeAlD
Vandetanib—YES1—Adaptive Immune System—NRAS—rectum cancer	0.000117	0.000247	CbGpPWpGaD
Vandetanib—FYN—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000117	0.000246	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—KRAS—rectum cancer	0.000116	0.000246	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—KRAS—rectum cancer	0.000116	0.000246	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—NRAS—rectum cancer	0.000116	0.000246	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—HRAS—rectum cancer	0.000116	0.000246	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—NRAS—rectum cancer	0.000115	0.000244	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—HRAS—rectum cancer	0.000115	0.000243	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—HRAS—rectum cancer	0.000115	0.000242	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—KRAS—rectum cancer	0.000115	0.000242	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000114	0.000241	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—KRAS—rectum cancer	0.000112	0.000237	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—HRAS—rectum cancer	0.000111	0.000234	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—HRAS—rectum cancer	0.00011	0.000233	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.00011	0.000232	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—KRAS—rectum cancer	0.000109	0.000231	CbGpPWpGaD
Vandetanib—MKNK1—Disease—KRAS—rectum cancer	0.000108	0.000229	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—TP53—rectum cancer	0.000107	0.000226	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—NRAS—rectum cancer	0.000106	0.000225	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—HRAS—rectum cancer	0.000106	0.000225	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—KRAS—rectum cancer	0.000105	0.000223	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—HRAS—rectum cancer	0.000105	0.000223	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—HRAS—rectum cancer	0.000105	0.000222	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—KRAS—rectum cancer	0.000105	0.000221	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—NRAS—rectum cancer	0.000105	0.000221	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—HRAS—rectum cancer	0.000104	0.000221	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—HRAS—rectum cancer	0.000104	0.000219	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TP53—rectum cancer	0.000103	0.000219	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—NRAS—rectum cancer	0.000103	0.000217	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—HRAS—rectum cancer	0.000102	0.000216	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—NRAS—rectum cancer	0.000102	0.000216	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—HRAS—rectum cancer	0.000101	0.000214	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—NRAS—rectum cancer	0.000101	0.000214	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—NRAS—rectum cancer	0.000101	0.000214	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—HRAS—rectum cancer	0.000101	0.000213	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—NRAS—rectum cancer	0.000101	0.000213	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—KRAS—rectum cancer	0.000101	0.000213	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—NRAS—rectum cancer	0.0001	0.000212	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—KRAS—rectum cancer	0.0001	0.000212	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—KRAS—rectum cancer	9.94e-05	0.00021	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—NRAS—rectum cancer	9.93e-05	0.00021	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—HRAS—rectum cancer	9.9e-05	0.000209	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—HRAS—rectum cancer	9.89e-05	0.000209	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—HRAS—rectum cancer	9.74e-05	0.000206	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TP53—rectum cancer	9.73e-05	0.000206	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—HRAS—rectum cancer	9.71e-05	0.000205	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—HRAS—rectum cancer	9.54e-05	0.000202	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—HRAS—rectum cancer	9.3e-05	0.000197	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—NRAS—rectum cancer	9.27e-05	0.000196	CbGpPWpGaD
Vandetanib—MKNK1—Disease—HRAS—rectum cancer	9.21e-05	0.000195	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—NRAS—rectum cancer	9.16e-05	0.000194	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—KRAS—rectum cancer	9.15e-05	0.000194	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—NRAS—rectum cancer	9.08e-05	0.000192	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—NRAS—rectum cancer	9.03e-05	0.000191	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—KRAS—rectum cancer	8.99e-05	0.00019	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—HRAS—rectum cancer	8.96e-05	0.000189	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—NRAS—rectum cancer	8.94e-05	0.000189	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—HRAS—rectum cancer	8.91e-05	0.000188	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—NRAS—rectum cancer	8.9e-05	0.000188	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TP53—rectum cancer	8.9e-05	0.000188	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—KRAS—rectum cancer	8.85e-05	0.000187	CbGpPWpGaD
Vandetanib—BLK—Immune System—NRAS—rectum cancer	8.81e-05	0.000186	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—NRAS—rectum cancer	8.81e-05	0.000186	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—KRAS—rectum cancer	8.8e-05	0.000186	CbGpPWpGaD
Vandetanib—FGR—Immune System—NRAS—rectum cancer	8.78e-05	0.000186	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—NRAS—rectum cancer	8.74e-05	0.000185	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—KRAS—rectum cancer	8.72e-05	0.000184	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—NRAS—rectum cancer	8.72e-05	0.000184	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—KRAS—rectum cancer	8.71e-05	0.000184	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—KRAS—rectum cancer	8.68e-05	0.000183	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—KRAS—rectum cancer	8.64e-05	0.000183	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—NRAS—rectum cancer	8.58e-05	0.000181	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—HRAS—rectum cancer	8.55e-05	0.000181	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—KRAS—rectum cancer	8.54e-05	0.000181	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—TYMS—rectum cancer	8.51e-05	0.00018	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—HRAS—rectum cancer	8.51e-05	0.00018	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—HRAS—rectum cancer	8.45e-05	0.000179	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—NRAS—rectum cancer	8.26e-05	0.000175	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TP53—rectum cancer	8.14e-05	0.000172	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—NRAS—rectum cancer	8.08e-05	0.000171	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—KRAS—rectum cancer	7.98e-05	0.000169	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—KRAS—rectum cancer	7.89e-05	0.000167	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—KRAS—rectum cancer	7.81e-05	0.000165	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—HRAS—rectum cancer	7.78e-05	0.000164	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—KRAS—rectum cancer	7.78e-05	0.000164	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—NRAS—rectum cancer	7.72e-05	0.000163	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—rectum cancer	7.71e-05	0.000163	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—KRAS—rectum cancer	7.69e-05	0.000163	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—rectum cancer	7.68e-05	0.000162	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—KRAS—rectum cancer	7.66e-05	0.000162	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—HRAS—rectum cancer	7.65e-05	0.000162	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—rectum cancer	7.59e-05	0.000161	CbGpPWpGaD
Vandetanib—BLK—Immune System—KRAS—rectum cancer	7.59e-05	0.00016	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—KRAS—rectum cancer	7.59e-05	0.00016	CbGpPWpGaD
Vandetanib—FGR—Immune System—KRAS—rectum cancer	7.56e-05	0.00016	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—KRAS—rectum cancer	7.52e-05	0.000159	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—HRAS—rectum cancer	7.52e-05	0.000159	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—KRAS—rectum cancer	7.5e-05	0.000159	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—TYMS—rectum cancer	7.49e-05	0.000158	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—HRAS—rectum cancer	7.48e-05	0.000158	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—NRAS—rectum cancer	7.46e-05	0.000158	CbGpPWpGaD
Vandetanib—ERBB3—Disease—NRAS—rectum cancer	7.46e-05	0.000158	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—NRAS—rectum cancer	7.44e-05	0.000157	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—NRAS—rectum cancer	7.41e-05	0.000157	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—HRAS—rectum cancer	7.41e-05	0.000157	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—HRAS—rectum cancer	7.4e-05	0.000156	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—KRAS—rectum cancer	7.39e-05	0.000156	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—HRAS—rectum cancer	7.38e-05	0.000156	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—HRAS—rectum cancer	7.34e-05	0.000155	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—NRAS—rectum cancer	7.32e-05	0.000155	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—HRAS—rectum cancer	7.26e-05	0.000154	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—NRAS—rectum cancer	7.14e-05	0.000151	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—KRAS—rectum cancer	7.11e-05	0.00015	CbGpPWpGaD
Vandetanib—YES1—Immune System—NRAS—rectum cancer	7.09e-05	0.00015	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—KRAS—rectum cancer	6.95e-05	0.000147	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—HRAS—rectum cancer	6.78e-05	0.000143	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—rectum cancer	6.74e-05	0.000143	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HRAS—rectum cancer	6.7e-05	0.000142	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—KRAS—rectum cancer	6.64e-05	0.00014	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—HRAS—rectum cancer	6.64e-05	0.00014	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—HRAS—rectum cancer	6.61e-05	0.00014	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—NRAS—rectum cancer	6.59e-05	0.000139	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—HRAS—rectum cancer	6.54e-05	0.000138	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HRAS—rectum cancer	6.51e-05	0.000138	CbGpPWpGaD
Vandetanib—BLK—Immune System—HRAS—rectum cancer	6.45e-05	0.000136	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—HRAS—rectum cancer	6.45e-05	0.000136	CbGpPWpGaD
Vandetanib—FGR—Immune System—HRAS—rectum cancer	6.43e-05	0.000136	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—KRAS—rectum cancer	6.42e-05	0.000136	CbGpPWpGaD
Vandetanib—ERBB3—Disease—KRAS—rectum cancer	6.42e-05	0.000136	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—KRAS—rectum cancer	6.4e-05	0.000135	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—HRAS—rectum cancer	6.4e-05	0.000135	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—KRAS—rectum cancer	6.38e-05	0.000135	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HRAS—rectum cancer	6.38e-05	0.000135	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—NRAS—rectum cancer	6.32e-05	0.000134	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—rectum cancer	6.32e-05	0.000134	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—KRAS—rectum cancer	6.3e-05	0.000133	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HRAS—rectum cancer	6.28e-05	0.000133	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—KRAS—rectum cancer	6.15e-05	0.00013	CbGpPWpGaD
Vandetanib—YES1—Immune System—KRAS—rectum cancer	6.1e-05	0.000129	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—HRAS—rectum cancer	6.05e-05	0.000128	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—NRAS—rectum cancer	5.92e-05	0.000125	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HRAS—rectum cancer	5.91e-05	0.000125	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—KRAS—rectum cancer	5.67e-05	0.00012	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HRAS—rectum cancer	5.65e-05	0.000119	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—rectum cancer	5.6e-05	0.000118	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—HRAS—rectum cancer	5.46e-05	0.000115	CbGpPWpGaD
Vandetanib—ERBB3—Disease—HRAS—rectum cancer	5.46e-05	0.000115	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KRAS—rectum cancer	5.44e-05	0.000115	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HRAS—rectum cancer	5.44e-05	0.000115	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HRAS—rectum cancer	5.42e-05	0.000115	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NRAS—rectum cancer	5.42e-05	0.000115	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—NRAS—rectum cancer	5.4e-05	0.000114	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—HRAS—rectum cancer	5.35e-05	0.000113	CbGpPWpGaD
Vandetanib—LYN—Immune System—NRAS—rectum cancer	5.29e-05	0.000112	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NRAS—rectum cancer	5.28e-05	0.000112	CbGpPWpGaD
Vandetanib—ABL1—Immune System—NRAS—rectum cancer	5.26e-05	0.000111	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HRAS—rectum cancer	5.23e-05	0.00011	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NRAS—rectum cancer	5.22e-05	0.00011	CbGpPWpGaD
Vandetanib—FYN—Immune System—NRAS—rectum cancer	5.2e-05	0.00011	CbGpPWpGaD
Vandetanib—YES1—Immune System—HRAS—rectum cancer	5.19e-05	0.00011	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KRAS—rectum cancer	5.1e-05	0.000108	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NRAS—rectum cancer	4.99e-05	0.000105	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NRAS—rectum cancer	4.94e-05	0.000104	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—NRAS—rectum cancer	4.92e-05	0.000104	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—rectum cancer	4.82e-05	0.000102	CbGpPWpGaD
Vandetanib—FYN—Disease—NRAS—rectum cancer	4.81e-05	0.000102	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NRAS—rectum cancer	4.75e-05	0.0001	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KRAS—rectum cancer	4.66e-05	9.86e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KRAS—rectum cancer	4.65e-05	9.82e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—rectum cancer	4.63e-05	9.78e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TYMS—rectum cancer	4.62e-05	9.76e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NRAS—rectum cancer	4.58e-05	9.69e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KRAS—rectum cancer	4.55e-05	9.62e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KRAS—rectum cancer	4.54e-05	9.61e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—rectum cancer	4.53e-05	9.58e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KRAS—rectum cancer	4.53e-05	9.57e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NRAS—rectum cancer	4.5e-05	9.51e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KRAS—rectum cancer	4.49e-05	9.5e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KRAS—rectum cancer	4.48e-05	9.47e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NRAS—rectum cancer	4.4e-05	9.31e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—rectum cancer	4.33e-05	9.16e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NRAS—rectum cancer	4.33e-05	9.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KRAS—rectum cancer	4.29e-05	9.07e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—rectum cancer	4.25e-05	8.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—rectum cancer	4.24e-05	8.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NRAS—rectum cancer	4.15e-05	8.78e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—rectum cancer	4.14e-05	8.76e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—rectum cancer	4.14e-05	8.74e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—rectum cancer	4.08e-05	8.63e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—rectum cancer	4.04e-05	8.54e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NRAS—rectum cancer	4e-05	8.46e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—rectum cancer	3.99e-05	8.44e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—rectum cancer	3.96e-05	8.38e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—rectum cancer	3.95e-05	8.35e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—rectum cancer	3.95e-05	8.34e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—rectum cancer	3.87e-05	8.18e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—rectum cancer	3.87e-05	8.18e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—rectum cancer	3.86e-05	8.16e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—rectum cancer	3.85e-05	8.14e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—rectum cancer	3.84e-05	8.11e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—rectum cancer	3.82e-05	8.08e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—rectum cancer	3.81e-05	8.05e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—rectum cancer	3.79e-05	8.01e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—rectum cancer	3.78e-05	7.99e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—rectum cancer	3.73e-05	7.88e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—rectum cancer	3.65e-05	7.71e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—rectum cancer	3.63e-05	7.67e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—rectum cancer	3.61e-05	7.64e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—rectum cancer	3.6e-05	7.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—rectum cancer	3.57e-05	7.55e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—rectum cancer	3.54e-05	7.49e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—rectum cancer	3.52e-05	7.43e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—rectum cancer	3.51e-05	7.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—rectum cancer	3.49e-05	7.38e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—rectum cancer	3.47e-05	7.34e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—rectum cancer	3.44e-05	7.28e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—rectum cancer	3.42e-05	7.23e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—rectum cancer	3.36e-05	7.11e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—rectum cancer	3.35e-05	7.09e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—rectum cancer	3.3e-05	6.98e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—rectum cancer	3.29e-05	6.95e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—rectum cancer	3.22e-05	6.81e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—rectum cancer	3.17e-05	6.7e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—rectum cancer	3.05e-05	6.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—rectum cancer	3.04e-05	6.42e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—rectum cancer	3e-05	6.35e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—rectum cancer	2.94e-05	6.22e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—rectum cancer	2.93e-05	6.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—rectum cancer	2.91e-05	6.15e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—rectum cancer	2.9e-05	6.12e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—rectum cancer	2.81e-05	5.93e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—rectum cancer	2.8e-05	5.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—rectum cancer	2.67e-05	5.65e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—rectum cancer	2.61e-05	5.53e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—rectum cancer	2.59e-05	5.48e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—rectum cancer	2.57e-05	5.44e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—rectum cancer	2.55e-05	5.4e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—rectum cancer	2.5e-05	5.29e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—rectum cancer	2.5e-05	5.29e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—rectum cancer	2.49e-05	5.27e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—rectum cancer	2.48e-05	5.24e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—rectum cancer	2.46e-05	5.2e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—rectum cancer	2.41e-05	5.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—rectum cancer	2.22e-05	4.7e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—rectum cancer	2.14e-05	4.53e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—rectum cancer	2.13e-05	4.51e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—rectum cancer	2.13e-05	4.5e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—rectum cancer	2.05e-05	4.33e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—rectum cancer	1.9e-05	4.01e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—rectum cancer	1.81e-05	3.84e-05	CbGpPWpGaD
